Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Standard Lithium in Final Stages of De-risking New Recovery Method; ...

Standard Lithium in Final Stages of De-risking New Recovery Method; Giant JV Partner Lanxess Will Fully Fund Capex When Successful The Critical Investor delves into this lithium firm's recovery method for its Arkansas project and why it may succeed when other companie...
Streetwise Reports | September 26, 2019 |

BioNTech, Gilead, Memphasys - modern science and COVID and IVF

People around the world are worried about the extent of the consequences associated with the spread of the corona virus COVID-19, and politicians and the economy are called upon to deal with the situation appropriately so that the loss of life and financial damage to the citiz...
Mario Hose | March 19, 2020 |

CureVac, BioNTech, Valeo Pharma: Where is there still potential?

The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company CureVac ( NASDAQ: CVAC ) recently started its phase study IIa in Peru and Panama. Around 700 people...
Nico Popp | October 16, 2020 |

Minimizing Mining Risk: The “Hybrid Opportunity Generator”

What sets certain companies apart from most others in the early-stage exploration space? A lot of the time it’s simply thinking outside of the box. In the case of Vancouver, BC-based junior exploration and development company Avrupa Minerals Ltd. (AVU)...
Dave Jackson | December 4, 2020 |

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data

Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. After U.S. markets closed for trading ye...
Streetwise Reports | January 29, 2020 |

ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates

Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. Clinical-stage biotechnology...
Streetwise Reports | February 18, 2020 |

Level up your trading with BMO InvestorLine’s enhanced features

With about 48 per cent of Canadians investing regularly, according to an Ipsos poll conducted in February, and more young people learning about the benefits of putting money to work than ever before, the demand for leading-edge trading platforms in terms of efficienc...
Trevor Abes | October 4, 2024 |

Gold, the Ultimate Safe Haven Asset. A Looming Nobel Prize?

Yesterday, the Nobel prizes in economics were awarded. Unfortunately, gold has been omitted and got nothing. How unfair! But looking at the Dutch central bank press release, gold would have much higher chances if they were the ones granting the prizes and not the Swedish ...
Arkadiusz Sieron | October 16, 2019 |

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial

Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price today after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturna...
Streetwise Reports | January 8, 2020 |
1 2 3 4